A Mendelian randomization study revealed pharmacologically distinct effects: while HMGCR inhibitors (i.e., statins) potentially increase melanoma risk, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (e.g., evolocumab, alirocumab) may confer protective effects.[144] Clinical evidence appears similarly inconsistent. The gene discussed is PCSK9; the disease is melanoma.